Molecular signalling pathways in canine gliomas

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


In this study, we determined the expression of key signalling pathway proteins TP53, MDM2, P21, AKT, PTEN, RB1, P16, MTOR and MAPK in canine gliomas using western blotting. Protein expression was defined in three canine astrocytic glioma cell lines treated with CCNU, temozolamide or CPT-11 and was further evaluated in 22 spontaneous gliomas including high and low grade astrocytomas, high grade oligodendrogliomas and mixed oligoastrocytomas. Response to chemotherapeutic agents and cell survival were similar to that reported in human glioma cell lines. Alterations in expression of key human gliomagenesis pathway proteins were common in canine glioma tumour samples and segregated between oligodendroglial and astrocytic tumour types for some pathways. Both similarities and differences in protein expression were defined for canine gliomas compared to those reported in human tumour counterparts. The findings may inform more defined assessment of specific signalling pathways for targeted therapy of canine gliomas.

Original languageEnglish (US)
JournalVeterinary and Comparative Oncology
StateAccepted/In press - 2015


  • Astrocytoma
  • Brain tumour
  • Canine glioma cell lines
  • Oligodendroglioma
  • Signalling pathways
  • Western blotting

ASJC Scopus subject areas

  • veterinary(all)


Dive into the research topics of 'Molecular signalling pathways in canine gliomas'. Together they form a unique fingerprint.

Cite this